Breaking News Instant updates and real-time market news.

T

AT&T

$32.11

0.03 (0.09%)

, BA

Boeing

$374.04

-0.98 (-0.26%)

20:25
04/23/19
04/23
20:25
04/23/19
20:25

Notable companies reporting before tomorrow's open

Notable companies reporting before tomorrow's open, with earnings consensus, include AT&T (T), consensus 86c... Boeing (BA), consensus $3.33... Thermo Fisher Scientific (TMO), consensus $2.73... Caterpillar (CAT), consensus $2.86... Anthem (ANTM), consensus $5.86... Norfolk Southern (NSC), consensus $2.18... General Dynamics (GD), consensus $2.42... Northrop Grumman (NOC), consensus $4.58... Boston Scientific (BSX), consensus 36c... Biogen (BIIB), consensus $6.84... Sirius XM (SIRI), consensus 5c... Stanley Black & Decker (SWK), consensus $1.11... Domino's Pizza (DPZ), consensus $2.09... Knight-Swift Transportation (KNX), consensus 52c... Owens Corning (OC), consensus 58c... Gentex (GNTX), consensus 39c.

T

AT&T

$32.11

0.03 (0.09%)

BA

Boeing

$374.04

-0.98 (-0.26%)

TMO

Thermo Fisher

$263.74

4.68 (1.81%)

CAT

Caterpillar

$142.08

-0.28 (-0.20%)

ANTM

Anthem

$250.75

6.71 (2.75%)

NSC

Norfolk Southern

$201.68

0.15 (0.07%)

GD

General Dynamics

$182.33

5.27 (2.98%)

NOC

Northrop Grumman

$292.59

9.73 (3.44%)

BSX

Boston Scientific

$35.88

0.95 (2.72%)

BIIB

Biogen

$229.89

1.15 (0.50%)

SIRI

Sirius XM

$6.14

0.03 (0.49%)

SWK

Stanley Black & Decker

$147.37

1.89 (1.30%)

DPZ

Domino's Pizza

$270.25

4.19 (1.57%)

KNX

Knight-Swift

$35.01

0.295 (0.85%)

OC

Owens Corning

$55.60

1.24 (2.28%)

GNTX

Gentex

$22.09

0.23 (1.05%)

  • 23

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 26

    Apr

  • 29

    Apr

  • 29

    Apr

  • 30

    Apr

  • 30

    Apr

  • 01

    May

  • 01

    May

  • 03

    May

  • 04

    May

  • 06

    May

  • 07

    May

  • 07

    May

  • 07

    May

  • 08

    May

  • 09

    May

  • 09

    May

  • 09

    May

  • 15

    May

  • 15

    May

  • 16

    May

  • 16

    May

  • 18

    May

  • 18

    May

  • 20

    May

  • 20

    May

  • 22

    May

  • 23

    May

  • 29

    May

  • 31

    May

  • 05

    Jun

  • 12

    Jun

  • 26

    Jun

  • 13

    Nov

  • 02

    Dec

T AT&T
$32.11

0.03 (0.09%)

03/27/19
JPMS
03/27/19
NO CHANGE
JPMS
Fundamentals across cable remain strong, says JPMorgan
Sustained household formation and wage growth, along with a pullback in promotional activity at AT&T (T), the main competitor to most multi-service operators, keeps fundamentals across cable strong, JPMorgan analyst Philip Cusick tells investors in a research note. In 2018, the U.S. added ~1.5m households for the second year in a row, "which sets up the wireline video and broadband ecosystems well in 2019," says the analyst. Altice USA (ATUS) and Charter Communications (CHTR) are both on the JPMorgan's Analyst Focus List, and Comcast (CMCSA) is Cusick's favorite mega-cap service provider. The analyst is "wary" of the multiple of Underweight-rated Cable One (CABO), but admits its operational momentum seems strong.
04/17/19
GSCO
04/17/19
NO CHANGE
GSCO
Sprint, T-Mobile headlines positive for Dish, Intelsat, says Goldman Sachs
Goldman Sachs analyst Brett Feldman, while taking no view on the outcome of the proposed merger between Sprint (S) and T-Mobile (TMUS), laid out his thoughts for other industry participants following the Wall Street Journal's report that the Department of Justice is unlikely to approve the deal as currently structured. The analyst believes investors will initially see the headlines as negative for the other major wireless carriers, namely AT&T (T) and Verizon (VZ), since they "create uncertainty over long-term industry structure." Further, investors will initially see these headlines as a slight positive for tower operators American Tower (AMT), Crown Castle (CCI) and SBA Communications (SBAC) as they "imply less risk of material cell site decommissioning," Feldman told investors earlier in a research note. The analyst also thinks investors will view the Journal's report as positive for owners of excess spectrum such as Dish (DISH) and Intelsat (I) and a slight positive for cable operators like Altice USA (ATUS), Charter (CHTR) and Comcast (CMCSA).
03/29/19
03/29/19
UPGRADE
Target $35

Buy
Viacom upgraded to Buy at Loop Capital on de-risked AT&T loss
As previously reported, Loop Capital analyst Alan Gould upgraded Viacom (VIAB) to Buy from Hold with a price target of $35. The analyst cites the company's loss of its biggest distributor AT&T (T) having been de-risked which, he believes, raises the likelihood of a Viacom merger with CBS (CBS). Gould adds that despite the renewed distribution deal with AT&T, investors can accumulate shares at a lower price than a few weeks ago, resulting in a "positive risk-reward" for Viacom.
04/05/19
04/05/19
UPGRADE
Target $36

Outperform
Viacom upgraded to Outperform from Sector Perform at RBC Capital
As previously reported, RBC Capital analyst Steven Cahall upgraded Viacom (VIAB) to Outperform from Sector Perform and raised his price target to $36 from $31, saying the company's "less contentious" than feared DirecTV (T) deal improves its standing and "paves the way toward merger talks" with CBS (CBS). The analyst sees an implied upside for Viacom stock at over 30% on the CBS deal prospects and believes that investors should own both to hedge the exchange ratio risk of the potential transaction.
BA Boeing
$374.04

-0.98 (-0.26%)

04/11/19
04/11/19
NO CHANGE

Boeing CEO says conducted 100 test flights with fixed 737 MAX software, WSJ says
The Wall Street Journal's Andrew Tangel reports that Boeing CEO Dennis Muilenburg, making his first public remarks since the Ethiopian Airlines crash of 737 MAX last month, indicated that the software changes being made will make the aircraft "even safer". Muilenburg noted that Boeing engineers have been "working tirelessly in collaboration with the Federal Aviation Administration to finalize and implement a software update that will ensure accidents like these never happen again". The CEO added that the company has already conducted nearly 100 test flights of the fixed 737 MAX software since it grounded the aircraft last month. Reference Link
04/18/19
WBLR
04/18/19
INITIATION
WBLR
Outperform
Woodward initiated with an Outperform at William Blair
William Blair analyst Nicholas Heymann started Woodward (WWD) with an Outperform rating saying the stock offers 15%-20% upside over the next 6-12 months. After six years of "robust" investment for new capacity and products, Woodward is entering a period of accelerating profitable organic growth. He believes the company is "exceptionally well positioned" to generate "sustainable" double-digit earnings growth despite the current Boeing (BA) 737 Max grounding.
04/22/19
IMPC
04/22/19
NO CHANGE
Target $43
IMPC
Outperform
American Airlines shares pricing in 737 Max issues, says Imperial Capital
Imperial Capital analyst Micheal Derchin believes shares of American Airlines (AAL) present an attractive risk/reward opportunity. Issues with Boeing's (BA) 737 MAX are largely priced into the stock, says the analyst, who sees upside potential on unit revenues. Further, current valuations reflect low expectations, Derchin tells investors in a research note. He keeps an Outperform rating on American Airlines with a $43 price target.
04/10/19
JPMS
04/10/19
NO CHANGE
Target $430
JPMS
Overweight
Boeing price target lowered to $430 from $450 at JPMorgan
JPMorgan analyst Seth Seifman lowered his price target for Boeing to $430 from $450 after updating his model for the company's "roughly in line" Q1 deliveries. However, "at this stage, modeling Boeing requires major assumptions for which there is little basis right now," Seifman tells investors in a research note. Uncertainties center around the span of the MAX delivery halt, how quickly Boeing might flush out MAX inventory when the halt is lifted, and how management plans to guide with Q1 results, says the analyst. He keeps an Overweight rating on Boeing shares.
TMO Thermo Fisher
$263.74

4.68 (1.81%)

04/22/19
NEED
04/22/19
NO CHANGE
Target $312
NEED
Strong Buy
Thermo Fisher price target raised to $312 from $271 at Needham
Needham analyst Stephen Unger raised his price target on Thermo Fisher to $312 and kept his Strong Buy rating ahead of its Q1 results this Wednesday. The analyst sees "solid potential" for an earnings beat on "better-than-expected organic revenue growth in all four segments", also noting that he has a "more bullish view" on the company's prospects for 2019. Unger adds that he is positive on the impact of the "strategic" Brammer Bio acquisition announced by Thermo Fisher last month.
03/26/19
BTIG
03/26/19
NO CHANGE
Target $310
BTIG
Buy
Thermo Fisher price target raised to $310 from $290 at BTIG
BTIG analyst Sung Ji Nam raised his price target on Thermo Fisher to $310 and kept his Buy rating after its announced $1.7B deal to buy Brammer Bio. The analyst sees "minimal" revenue and earnings impact from the purchase in the near term but sees the company "gaining valuable capabilities to support one of the fastest growing areas within the biopharma end market" as a result of the transaction. Sung Ji Nam concludes that the acquisition makes "financial sense" given Thermo Fisher's "successful foray" into the contract development and manufacturing organization, or CDMO, market.
03/26/19
BARD
03/26/19
NO CHANGE
Target $288
BARD
Outperform
Thermo Fisher price target raised to $288 from $270 at Baird
Baird analyst Catherine Ramsey Schulte reiterated an Outperform rating on Thermo Fisher and raised her price target to $288 from $270 following the company's announcement that it will buy Brammer Bio for $1.7B. In a research note to investors, the analyst says she continues to recommend Thermo Fisher as a core holding, and sees room for organic outperformance throughout 2019 as well as the potential for additional M&A.
03/25/19
DBAB
03/25/19
NO CHANGE
Target $300
DBAB
Buy
Thermo Fisher price target raised to $300 from $275 at Deutsche Bank
Deutsche Bank analyst Dan Leonard raised his price target for Thermo Fisher to $300 from $275 saying the acquisition of Brammer Bio fills the gap in its contract services offering. The analyst believes Thermo Fisher can continue to exceed market growth rates "despite uniquely challenging comps." He says the acquisition supports his thesis and keeps a Buy rating on the shares.
CAT Caterpillar
$142.08

-0.28 (-0.20%)

04/12/19
FBCO
04/12/19
NO CHANGE
Target $173
FBCO
Outperform
Caterpillar 'set up well' with conservatism around guidance, says Credit Suisse
Credit Suisse analyst Jamie Cook reiterated an Outperform rating on Caterpillar and said the stock is her top pick following dealer survey results, which indicated that for 2019, 90% of dealers reiterated prior forecasts calling for demand to be up 5%. Additionally, Cook says rising commodity prices, particularly oil and copper, bode well for Caterpillar going forward. She believes Caterpillar is set up well with enough conservatism around its 2019 guidance.
04/10/19
MSCO
04/10/19
NO CHANGE
Target $165
MSCO
Overweight
Caterpillar mining growth can offset construction declines, says Morgan Stanley
Morgan Stanley analyst Courtney Yakavonis noted that while some parts of Caterpillar's portfolio are "clearly approaching peak," she believes the consensus view is "embedding an overly draconian scenario for 2020." She expects Construction segment revenue declines of 2%-5% in 2020/2021 to be offset by growth in both Mining and the other 45% of Caterpillar's portfolio that likely remains below mid-cycle, Yakavonis tells investors. In particular, she believes the market is underappreciating the potential growth within Caterpillar's Mining business through 2022, stating that she expect 8% average revenue growth in Caterpillar's Resource division to offset Construction declines. Yakavonis raised her price target on Caterpillar shares to $165 from $160 and keeps an Overweight rating on the stock.
04/04/19
UBSW
04/04/19
NO CHANGE
Target $125
UBSW
Sell
Caterpillar may see downside in 2020 on slower replacement demand, says UBS
UBS analyst Steven Fisher kept his Sell rating and $125 price target on Caterpillar. The analyst notes that while the findings of UBS's China Industrial team suggest a "faster than expected recovery in construction activities" along with stronger than expected sales following the Chinese New Year, the company may see a softening replacement demand in 2020 after acceleration in 2019.
04/03/19
04/03/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Caterpillar (CAT) downgraded to Hold from Buy at Deutsche Bank with analyst Chad Dillard saying the biggest risk to the bull case for Caterpillar is if its backlog growth turns negative, "and it is becoming increasingly clear that it will within this next quarter." 2. Dunkin' Brands (DNKN) downgraded to Market Perform from Outperform at BMO Capital with analyst Andrew Strelzik saying that while he remains positive on the company's underlying fundamentals over the long term, he sees risk/reward at current levels as "less persuasive." 3. Tallgrass Energy (TGE) downgraded to Neutral from Buy at Goldman Sachs with analyst Michael Lapides citing the stock's recent outperformance and also warns that its Rockies Express Pipeline natural gas pipeline and Pony Express crude oil pipeline contract roll-offs pose "overhangs," even though the "volume growth out of Bakken, Niobrara, and Powder River Basin could offset this over time." 4. Walgreens Boots Alliance (WBA) downgraded to Hold from Buy at Loop Capital with analyst Andrew Wolf citing the company's disappointing Q2 earnings and FY19 guidance announced yesterday "driven by significantly lower-than-forecasted gross margin resulting from increased pharmacy reimbursement rate pressure in the U.S." 5. Alcoa (AA) downgraded to Neutral from Buy at BofA/Merrill with analyst Timna Tanners saying she now sees limited free cash flow payments by Alcoa to upstream AWAC joint-venture partner Alumina Ltd, potential excess alumina/bauxite supply, and potential price risks from the Alunorte refinery restarting, the world's largest refinery. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
ANTM Anthem
$250.75

6.71 (2.75%)

03/29/19
03/29/19
DOWNGRADE

WellCare downgraded to Hold at Argus on Centene merger
Argus analyst David Toung downgraded WellCare (WCG) to Hold after it agreed to be acquired by Centene (CNC) in a $17.3B deal or at $305.39 per share. The analyst notes that because the deal would yield an entity that is smaller than the insurance industry giants, it may receive a more favorable treatment from the regulators than the failed Aetna (AET) -Humana (HUM) and Anthem (ANTM)-Cigna (CI) deals, but warns that some antitrust scrutiny is still possible due to overlaps between the companies in a few states. Toung adds that the new company would have "strengths in Medicare Advantage and Medicaid, both of which are growing markets."
04/17/19
SPHN
04/17/19
NO CHANGE
SPHN
Issues facing healthcare sector now 'modest' compared to 2008-10, says Stephens
Stephens analyst Scott Fidel noted that the managed care group has sharply underperformed the S&P 500 over the last month amid "political rhetoric" around point-of-sale drug rebates and Medicare for all policy proposals, though he believes the issues facing the sector right now "seem modest in comparison" to the "dark days of 2008-2010." While recent Medicare for all proposals have rattled investors, "they will face enormous uphill battles," Fidel tells investors. Hospital stocks have outperformed MCOs year-to-date, but the group declined about 9% yesterday and underperformed the MCO group, which Fidel attributes to acknowledgement by industry bellwether UnitedHealth (UNH) of the significant disruptive nature of Medicare for all, which may have sparked additional fears, as well as one less calendar day being called out by UnitedHealth as benefiting Q1 MLRs and Johnson & Johnson's (JNJ) earnings call commentary on declining sequential hospital admissions from Q4. Publicly traded companies in the hospital space include Community Health (CYH), HCA Healthcare (HCA), LifePoint (LPNT), Tenet (THC) and Universal Health (UHS). Publicly traded companies in the managed care space include Anthem (ANTM), CVS Health (CVS), Centene (CNC), Cigna (CI), Health Net (HNT), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG).
04/18/19
LEER
04/18/19
NO CHANGE
LEER
Medicare-For-All risk overblown, investors should buy MCOs, says SVB Leerink
SVB Leerink analyst Ana Gupte believes Medicare-For-All risk is overblown, not the same as 2008/09, and recommends investors step in now to buy MCOs. The analyst believes it is a "once in a decade opportunity" to get high quality names at these depressed multiples, with UnitedHealth (UNH), Anthem (ANTM), and Humana (HUM) being her favorites.
04/23/19
UBSW
04/23/19
INITIATION
Target $294
UBSW
Buy
Anthem initiated with a Buy at UBS
UBS analyst Whit Mayo started Anthem with a Buy rating and $294 price target. The analyst forecasts "industry-leading" 20% earnings growth through 2020. Current share levels price in negative long-term growth, resemble 2012-2013 sector discounts, and offer up a favorable 2.2:1 upside/downside, Mayo tells investors in a research note.
NSC Norfolk Southern
$201.68

0.15 (0.07%)

03/13/19
LEHM
03/13/19
NO CHANGE
Target $200
LEHM
Equal Weight
Barclays recommends taking patient approach to Norfolk Southern shares
While Norfolk Southern appears to have the right plan in place, being patient with the stock is the proper approach, Barclays analyst Brandon Oglenski tells investors in a research note. If management can deliver traction on margin expansion, the upside "could be significant," but "lofty" revenue expectations could prove challenging in 2019, given a softer start to the year, says the analyst. He believes Norfolk "still has a lot to learn on the path to becoming a Precision Scheduled Railroad." Oglenski raised his price target for the shares to $200 from $190 and keeps an Equal Weight rating on the name.
04/01/19
BOFA
04/01/19
UPGRADE
Target $205
BOFA
Buy
Norfolk Southern upgraded to Buy on rapid gains at BofA/Merrill
As previously reported, BofA/Merrill upgraded Norfolk Southern to Buy from Neutral with a $205 price target. Analyst Ken Hoexter said Norfolk has had a rapid improvement from its Precision Scheduled Rail overhaul and is posting continued gains in its performance metrics with velocity up 9% year-to-date and Dwell up 35% since the start of the year. Norfolk is gaining on its Precision Scheduled Rail goals and the Street is too conservative versus the company's potential, the analyst wrote in a note to investors.
04/08/19
ARGS
04/08/19
NO CHANGE
Target $210
ARGS
Buy
Norfolk Southern price target raised to $210 from $180 at Argus
Argus analyst John Eade raised his price target on Norfolk Southern to $210 and kept his Buy rating, saying he sees "solid demand for the industry" and volume trends having turned positive. The analyst also points to the company's accelerating its "aggressive restructuring program that is lowering costs and improving profitability", adding that the management's decision to raise dividend payments 3 times in the past year also signals its confidence about its outlook. Eade further notes Norfolk Southern's clean balance sheet and offers a positive view for the North American railroad companies "based on strength in the consumer sector, as well as fuel prices that remain well below 2013-2014 levels."
04/01/19
BOFA
04/01/19
UPGRADE
BOFA
Buy
Norfolk Southern upgraded to Buy from Neutral at BofA/Merrill
GD General Dynamics
$182.33

5.27 (2.98%)

02/15/19
02/15/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Coca-Cola (KO) downgraded to Neutral from Buy at Citi with analyst Wendy Nicholson saying the company's guidance implies 2019 earnings growth of plus or minus 1%. Coca-Cola has reported earnings per share of $2.00, plus or minus 10c, for the last eight years, with strong underlying growth offset by dilution from refranchising activities and currency headwinds. 2. General Dynamics (GD) downgraded to Neutral from Outperform at Credit Suisse with analyst Robert Springarn saying the acquisition of CSRA appears to be only "nominally accretive" to 2019, well short of his expectations, and says he believes the acquisition has significantly reduced the company's balance sheet flexibility and may limit future shareholder returns. 3. Ball Corp. (BLL) downgraded to Neutral from Buy at UBS with analyst Edlain Rodriguez saying while Ball's fundamentals "remain solid," a higher multiple "is a stretch" with the stock already up 45% over the past year. 4. Six Flags (SIX) downgraded to Sector Weight from Overweight at KeyBanc with analyst Brett Andress saying he remains constructive on the broader theme park industry and the majority of Six Flags' growth pillars, but international upside had been a key component of his thesis and the significantly reduced visibility and potential downside prompts the downgrade. 5. LogMeln (LOGM) downgraded to Perform from Outperform at Oppenheimer and to Hold from Buy at Needham. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, Reference Link
02/04/19
BERN
02/04/19
NO CHANGE
Target $178
BERN
Market Perform
General Dynamics price target lowered to $178 from $186 at Bernstein
Bernstein analyst Douglas Harned lowered his price target for General Dynamics to $178 from $186 after the company reported solid Q4 results, but several issues raised more caution for short-term sentiment on the stock. The analyst reiterates a Market Perform rating on the shares.
02/15/19
FBCO
02/15/19
DOWNGRADE
Target $184
FBCO
Neutral
General Dynamics downgraded to Neutral from Outperform at Credit Suisse
Credit Suisse analyst Robert Springarn downgraded General Dynamics to Neutral from Outperform and lowered his price target to $184 from $190. In a research note to investors, Springarn says the acquisition of CSRA appears to be only "nominally accretive" to 2019, well short of his expectations, and says he believes the acquisition has significantly reduced the company's balance sheet flexibility and may limit future shareholder returns. Additionally, Springarn sees increasing competitive threats in both IT and Aerospace, which dims his growth outlook. Springarn says he is no longer convinced that General Dynamics can outperform, at least until management can show that its strategy warrants a higher multiple.
02/15/19
FBCO
02/15/19
DOWNGRADE
FBCO
Neutral
General Dynamics downgraded to Neutral from Outperform at Credit Suisse
NOC Northrop Grumman
$292.59

9.73 (3.44%)

04/05/19
04/05/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Bed Bath & Beyond (BBBY) upgraded to Equal Weight from Underweight at Morgan Stanley with analyst Simeon Gutman saying he believes activist intervention presents the potential for upside for the stock in the near-term. 2. Snap (SNAP) upgraded to Hold from Sell at Summit Insights. 3. Northrop Grumman (NOC) upgraded to Positive from Neutral at Susquehanna. 4. Weyerhaeuser (WY) upgraded to Overweight from Equal Weight at Stephens with analyst Mark Connelly saying the stock, which is generally viewed as an income play, has sold off on rate concerns and slower starts. 5. Viacom (VIA, VIAB) upgraded to Outperform from Sector Perform at RBC Capital with analyst Steven Cahall saying the company's "less contentious" than feared DirecTV (T) deal improves its standing and "paves the way toward merger talks" with CBS (CBS). This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/05/19
SUSQ
04/05/19
UPGRADE
Target $315
SUSQ
Positive
Northrop Grumman upgraded to Positive from Neutral at Susquehanna
Susquehanna analyst Charles Minervino upgraded Northrop Grumman to Positive from Neutral and raised his price target on the shares to $315 from $309.
02/01/19
02/01/19
DOWNGRADE

Buy
Goldman removes Northrop Grumman from Conviction List due to near-term concerns
As previously reported, Goldman Sachs analyst Noah Poponak removed Northrop Grumman from the firm's Conviction List as the company is guiding that top-line outgrowth will not happen in 2019 or 2020. " They often beat revenue guidance but we may not see that in the near-term," Poponak stated in his note to investors. However, he still thinks Northrop will post several years of fast organic revenue growth into the middle of next decade given its long list of major program wins and he maintains a Buy rating on the stock.
02/01/19
GSCO
02/01/19
DOWNGRADE
GSCO
Buy
Northrop Grumman downgraded to Buy from Conviction Buy at Goldman Sachs
BSX Boston Scientific
$35.88

0.95 (2.72%)

04/23/19
PIPR
04/23/19
NO CHANGE
Target $42
PIPR
Overweight
Boston Scientific Lotus approval may accelerate share gains, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien kept his Overweight rating and $42 price target on Boston Scientific after its "long anticipated" FDA approval of Lotus Edge transcatheter aortic valve replacement, or TAVR, product. The analyst believes that with the combination of differentiated features and the "buzz at previous medical conferences" about the relaunch may accelerate the company's market share capture in the TAVR space. O'Brien calls today's news a "strong positive" for the stock given the "recent transvaginal surgical mesh notice and paclitaxel concerns."
04/16/19
WELS
04/16/19
NO CHANGE
WELS
Boston Scientific mesh sales impacted by FDA recall about $25M, says Wells Fargo
Wells Fargo analyst Larry Biegelsen says that Boston Scientific has informed him that total mesh sales are about $100M and that the products impacted by the FDA recall represent a subset of those sales or about $25M or 0.3% of total sales. The firm had previously stated that the mesh sales impacted by the FDA recall were about $100M in 2018. Biegelsen notes that the lower figure should be "more manageable" for the company. According to the analyst, Boston Scientific is surprised and disappointed by the FDA's decision, which impacts Uphold LITE Vaginal Support System and the Xenform Soft Tissue Repair Matrix for pelvic organ prolapse.
04/16/19
PIPR
04/16/19
NO CHANGE
Target $42
PIPR
Overweight
Boston Scientific should be bought on surgical mesh selloff, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien recommends using the selloff today in shares of Boston Scientific after the FDA ordered all manufacturers of surgical mesh intended for transvaginal repair to stop selling and distributing their products immediately as a buying opportunity. Mesh products have been declining for several years at Boston Scientific and represented only ~1% of revenue in 2018, O'Brien tells investors in an intraday research note. The analyst estimates the company's revenue will be negatively impacted by less than $50M in 2019. Further, Boston Scientific is currently working with the FDA on a resolution, adds the analyst. Boston Scientific still has a "plethora of high-growth product launches fully intact" including Lotus, Acurate neo, and Watchman in Japan, "which should help cushion any lost revenue," says O'Brien. He has an Overweight rating on the shares with a $42 price target. The stock in afternoon trading is down 4% to $36.34.
04/16/19
PIPR
04/16/19
NO CHANGE
Target $42
PIPR
Overweight
Boston Scientific selloff today a buying opportunity, says Piper Jaffray
BIIB Biogen
$229.89

1.15 (0.50%)

04/10/19
RAJA
04/10/19
INITIATION
RAJA
Market Perform
Biogen resumed with a Market Perform at Raymond James
Raymond James analyst Steven Seedhouse resumed coverage of Biogen with a Market Perform rating, stating that the company's remaining business following the failure of aducanumab "appears a little fragile" and faces "existential risk" in some cases, such as the Tecfidera IPR decision due in 2020. Near-term pipeline readouts, including the nearest readouts on Vumerity and BIIB067, don't seem high-impact enough to reverse sentiment, Seedhouse tells investors.
04/11/19
BERN
04/11/19
INITIATION
Target $48
BERN
Outperform
PTC Therapeutics initiated with an Outperform at Bernstein
Bernstein analyst Vincent Chen started coverage on PTC Therapeutics (PTCT) with an Outperform rating and a $48 price target, given his positive view on the commercial potential of risdiplam in SMA. The analyst believes that there will still be a substantial market opportunity for non-gene therapy drugs after approval, and thinks risdiplam's oral dosing will be a substantial advantage over Biogen (BIIB) Spinraza's intrathecal administration. If risdiplam is safe and comparably efficacious to Spinraza, Chen forecasts potential for $2.5B in revenues by 2030.
03/26/19
PIPR
03/26/19
NO CHANGE
Target $280
PIPR
Overweight
Piper continues to recommend Biogen shares after deeper dive on BIIB067
Piper Jaffray analyst Christopher Raymond continues to recommend Biogen shares after a deeper dive on BIIB067, an anti-sense oligonucleotide targeting SOD1 for the treatment of SOD1-amyotrophic lateral sclerosis. With the recent discontinuation of aducanumab in mild Alzheimer's disease, the company's amyotrophic lateral sclerosis anti-sense oligonucleotide programs could help dispel the notion that Biogen has no pipeline, Raymond tells investors in a research note. He thinks the BIIB067 and BIIB078 programs could add $10 and $15, respectively, to the stock if successful. Raymond keeps an Overweight rating on Biogen with a $280 price target. The stock closed yesterday up $3.55 to $220.26.
04/02/19
PIPR
04/02/19
NO CHANGE
PIPR
Overweight
Piper says AAN meeting should be 'meaningful' for Alexion, Biogen
Piper Jaffray analyst Christopher Raymond reported that the American Academy of Neurology posted emerging science abstract titles this morning, adding that full abstracts are not anticipated until May 3. It appears Phase 3 data on Alexion's (ALXN) Soliris for Neuromyelitis Optica Spectrum Disorder, or NMOSD, will be presented as an emerging science abstract and that data from a Phase 1/2 study of Biogen's (BIIB) BIIB067 in SOD1 mutant ALS patients will also be presented, making the meeting potentially "meaningful" for both. Raymond keeps Overweight ratings on Alexion and Biogen.
SIRI Sirius XM
$6.14

0.03 (0.49%)

01/30/19
01/30/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. United Continental (UAL) initiated with a Buy at Argus. 2. Amicus (FOLD) initiated with an Overweight at Cantor Fitzgerald. 3. Take-Two (TTWO) and Zynga (ZNGA) were initiated with a Buy at Goldman Sachs, while Electronic Arts (EA) and Activision Blizzard (ATVI) were initiated with a Neutral. 4. Sirius XM (SIRI) resumed with a Buy at B. Riley. 5. National Grid (NGG) initiated with an Overweight at Barclays. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/29/19
RILY
01/29/19
INITIATION
Target $8
RILY
Buy
Sirius XM resumed with a Buy at B. Riley
B. Riley resumed Sirius XM with a Buy rating and a price target of $8.
03/15/19
MSCO
03/15/19
INITIATION
Target $6.5
MSCO
Equal Weight
Sirius XM resumed with an Equal Weight at Morgan Stanley
Morgan Stanley analyst Benjamin Swinburne resumed coverage of Sirius XM (SIRI) with an Equal Weight rating and $6.50 price target, noting that acquiring Pandora with shares was dilutive to free cash flow per share but something he considers "a relatively low risk bet." He expects pro forma SiriusXM to grow revenue and adjusted EBITDA at a 6% and 9% 5-year CAGR respectively from 2019-2023. Swinburne also resumed coverage of Liberty Sirius XM (LSXMK) with an Overweight rating.
01/28/19
01/28/19
UPGRADE
Target $7.25

Buy
Sirius XM upgraded to Buy on Pandora approval boost at Buckingham
As previously reported, Buckingham upgraded Sirius XM (SIRI) to Buy from Neutral and maintained a $7.25 price target. Analyst Matthew Harrigan expects a favorable Pandora (P) shareholder vote tomorrow to approve Sirius' acquisition and management to reiterate transaction benefits on the Q4 conference call on Wednesday. Harrigan said spectrum ownership and Pandora synergies increases Sirius' 2019 upside potential to $9.25
SWK Stanley Black & Decker
$147.37

1.89 (1.30%)

04/16/19
VERT
04/16/19
NO CHANGE
VERT
Stanley Black & Decker removed from top picks list at Vertical Research
03/22/19
LBOW
03/22/19
UPGRADE
Target $160
LBOW
Buy
Stanley Black & Decker upgraded to Buy on Craftsman deal benefits at Longbow
As previously reported, Longbow analyst David Macgregor upgraded Stanley Black & Decker to Buy from Neutral citing his analysis of its opportunity with the Craftsman brand through 2022. Macgregor forecasts that the investment in Craftsman and associated initiatives are capable of driving over $1.1B of 2022 revenue and 94c in incremental adjusted EPS and views the company as well-positioned to hit their targeted $12B-$14B of 2022 Tools & Storage revenue. He also views the shares as oversold and would recommend a more aggressive purchase on any weakness around the Q1 earnings report, said Macgregor, who has a $160 price target on Stanley Black & Decker shares.
03/06/19
WELS
03/06/19
NO CHANGE
Target $150
WELS
Outperform
Stanley Black & Decker price target raised to $150 from $141 at Wells Fargo
Wells Fargo analyst Rich Kwas raised his price target for Stanley Black & Decker to $150 from $141 after meeting with the company's CFO Don Allan. Overall, the analyst believes the earnings set up is better versus a year ago and there is more room for outperformance than not. Longer-term, there is good opportunity to structurally improve gross margin via greater use of technology in manufacturing, procurement improvement, and better pricing execution, he contends. Kwas reiterates an Outperform rating on the shares.
03/22/19
LBOW
03/22/19
UPGRADE
LBOW
Buy
Stanley Black & Decker upgraded to Buy from Neutral at Longbow
DPZ Domino's Pizza
$270.25

4.19 (1.57%)

04/17/19
04/17/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Qualcomm (QCOM) upgraded to Overweight from Neutral at JPMorgan and to Outperform from In Line at Evercore ISI. 2. Domino's Pizza (DPZ) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst John Glass saying he thinks the stock's current price reflects 2-3% blended global same store sales growth over the next two years, which he views as too bearish based on its track record as a "best in class operator." 3. TSYS (TSS) upgraded to Buy from Neutral at Goldman Sachs with analyst James Schneider saying the company's new portfolios are driving revenue growth while improving margin expansion is driving earnings acceleration. 4. Omnicom (OMC) upgraded to Equal Weight from Underweight at Barclays. 5. Jones Lang LaSalle (JLL) upgraded to Outperform from Market Perform at Keefe Bruyette with analyst Jade Rahmani saying she sees an attractive entry point following the recent underperformance of the shares. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/16/19
WELS
04/16/19
NO CHANGE
Target $240
WELS
Market Perform
Domino's Pizza price target lowered to $240 from $250 at Wells Fargo
Wells Fargo analyst Jon Tower lowered his price target for Domino's Pizza to $240 from $250 ahead of quarterly results. The analyst sees risks to Q1 and 2019 EPS, which may keep multiple expansion at bay in the near-term. Further, Tower believes investor concerns around incremental competition in delivery and value will grow louder if global same-store sales come in shy of already muted expectations. He reiterates a Market Perform rating on the shares.
04/17/19
MSCO
04/17/19
UPGRADE
MSCO
Overweight
Domino's Pizza upgraded to Overweight from Equal Weight at Morgan Stanley
04/17/19
MSCO
04/17/19
UPGRADE
Target $283
MSCO
Overweight
Morgan Stanley says Domino's Pizza growth undervalued, upgrades to Overweight
As previously reported, Morgan Stanley analyst John Glass upgraded Domino's Pizza (DPZ) to Overweight from Equal Weight, stating that he thinks the stock's current price reflects 2-3% blended global same store sales growth over the next two years, which he views as too bearish based on its track record as a "best in class operator." Based on third party data on Domino's Q1 app downloads, Glass sees evidence that the market's concerns over decelerating U.S. comps may be overdone, he added. Following recent weakness, Domino's shares now trade at parity with Yum! Brands (YUM), which Glass calls "a high quality but slower growing peer" and not much of a premium to Dunkin' Brands (DNKN), which he calls "a far slower growing business." He raised his price target on Domino's shares to $283 from $268.
KNX Knight-Swift
$35.01

0.295 (0.85%)

01/22/19
DBAB
01/22/19
NO CHANGE
DBAB
Buy
Deutsche Bank names Werner short-term investment idea
Deutsche Bank analyst Amit Mehrotra placed a "Catalyst Call" on Werner Enterprises (WERN) as a short-term investment idea. Despite the recent rally in U.S. Transportation stocks, Werner shares still trade at a "meaningful discount" to fair value at this point in the cycle, Mehrotra tells investors in a research note. He points out that the stock has significantly lagged peer Knight-Swift (KNX) year-to-date. The analyst keeps a Buy rating on Werner.
03/05/19
MSCO
03/05/19
UPGRADE
Target $25
MSCO
Equal Weight
Echo Global upgraded to Equal Weight from Underweight at Morgan Stanley
Morgan Stanley analyst Ravi Shanker upgraded Echo Global (ECHO) to Equal Weight and raised his price target to $25 from $22 as part of his broader research note recommending that investors buy Truck Load names. The analyst contends that the behavior of the industry over the past 6 months suggests a "potential structural bull case of rates re-basing higher" and expects the industry multiples to re-rate higher as well. Shanker anticipates 25%-50% upside to Truck Load stocks from their current levels. Outside of Echo Global, the analyst also highlights Knight Swift (KNX), Schneider National (SNDR), Werner Enterprises (WERN), and U.S. Xpress Enterprises (USX) as his "top picks" in the Freight Transportation sector, saying they trade "below trough valuation" despite better than expected 2019 guidance.
02/01/19
LOOP
02/01/19
NO CHANGE
LOOP
Loop Capital says take advantage of pullback in Knight-Swift
Loop Capital analyst Jeffrey Kauffman reaffirmed a Buy rating and $47 price target on Knight-Swift shares after the company reported better-than-expected Q4 results driven by strong margin improvement, which the analyst believes demonstrates that management "seems to be getting their hands around the former Swift business." Kauffman said he believes "investors are being given the opportunity to take advantage of a pullback in the stock."
01/22/19
WOLF
01/22/19
DOWNGRADE
WOLF
Peer Perform
Knight-Swift downgraded to Peer Perform from Outperform at Wolfe Research
OC Owens Corning
$55.60

1.24 (2.28%)

03/11/19
JEFF
03/11/19
NO CHANGE
JEFF
Jefferies upgrades Materials sector to Market Weight from Underweight
Jefferies analyst Steven DeSanctis upgraded the Materials sector to Market Weight from Underweight citing early signs of "green shoots" in China, a turn in the inventory cycle, and housing data that "does not look as bad as the stocks reflected in 2018." The analyst says Jefferies likes industries associated with housing and would be selective in Metals & Mining. The firm is Overweight Technology, Discretionary, Industrials and Energy.
02/26/19
ZELM
02/26/19
DOWNGRADE
ZELM
Hold
Owens Corning downgraded to Hold from Buy at Zelman
02/05/19
LEHM
02/05/19
NO CHANGE
Target $58
LEHM
Overweight
Owens Corning risk/reward favorable into Q4 results, says Barclays
Barclays analyst Matthew Bouley sees a favorable risk/reward for Owens Corning into its Q4 results following his "positive" insulation distributor checks. While ARMA data driving potential upside to Q4 is now well-appreciated, price realization in Insulation is an incremental positive supporting 2019 estimates, Bouley tells investors in a pre-earnings research note. The analyst also believes Owens shares do not fully reflect the potential benefits of lower asphalt prices, which he thinks "lend support in light of broader demand uncertainty." He keeps an Overweight rating on Owens Corning with a $58 price target.
03/26/19
JPMS
03/26/19
NO CHANGE
Target $36.5
JPMS
Neutral
Beacon Roofing Q2 miss negative for Owens Corning, says JPMorgan
Largely driven by the quarter's harsh weather, Beacon Roofing Supply (BECN) last night announced weaker than expected preliminary Q2 results, JPMorgan analyst Michael Rehaut tells investors in a research note. The preannouncement is a negative read-through for Owens Corning (OC), adds the analyst, who points out that his Q1 earnings per share estimate of 52c is already below the Street's 61c consensus. The analyst keeps a Neutral rating on Beacon Roofing with a $36.50 price target. The stock's valuation appropriately reflects the company's temporarily elevated leverage, recent challenges surrounding sales consistency and guidance, as well as upside potential over the next two years from the Allied integration, says Rehaut.
GNTX Gentex
$22.09

0.23 (1.05%)

12/28/18
BUCK
12/28/18
NO CHANGE
Target $32
BUCK
Buy
DOT approval a 'significant catalyst' for Stoneridge shares, says Buckingham
Buckingham analyst Glenn Chin reiterates a Buy rating on Stoneridge (SRI) with a $32 price target after the Department of Transportation approved the company's application for commercial vehicles to operate with the MirrorEye camera monitoring system in lieu of two rear-vision mirrors as previously required by law. The approval provides an exemption for the Stoneridge MirrorEye system only, and does not apply to competing camera monitoring systems, Chin tells investors in a research note. He believes the development provides Stoneridge with a "significant" competitive advantage in the U.S. Further, the approval provides a "significant catalyst" for Stoneridge shares and further reinforces the business case for customer adoption of MirrorEye, says the analyst. Alternatively, Chin expects competitor Gentex (GNTX) to come under pressure following the decision. He has an Underperform rating on those shares. Stoneridge is up 2% to $23.45 in morning trading while Gentex is down 9c to $19.99.
01/28/19
BMOC
01/28/19
NO CHANGE
BMOC
BorgWarner, Gentherm, Visteon, Autolive price targets raised at BMO Capital
BMO Capital analyst Richard Carlso is turning more bullish on the auto and mobility equipment industry, saying the sentiment from the most recent CES, Detroit Auto Show, and GM's (GM) Capital Markets Day events has shifted his outlook from "cautious" to "cautiously optimistic". The analyst attributes the snap-back rally in the sector stocks' prices to increased optimism over the impact of lingering trade issues and outlooks from companies that have so far updated on their Q4 performance, all of which suggested that the 2018-end declines were overextended. Carlson is raising his price target on Autoliv (ALV) to $84 from $79, on Gentex (GNTX) to $27 from $24, on Aptiv (APTV) to $84 from $74, on Veoneer (VNE) to $41 from $36, on BorgWarner (BWA) to $49 from $44, and on Visteon (VC) to $91 from $84.
02/05/19
LBOW
02/05/19
DOWNGRADE
LBOW
Neutral
Gentex downgraded to Neutral from Buy at Longbow
Longbow analyst Anthony Deem downgraded Gentex to Neutral.
02/05/19
02/05/19
DOWNGRADE

Neutral
Gentex downgraded to Neutral on slowing growth at Longbow
As previously reported, Longbow analyst Anthony Deem downgraded Gentex to Neutral from Buy, citing his view that growth over market is slowing in the near-term and the pressure he expects on gross margins from tariffs and price downs that are not fully offset by lower purchase costs. He also believes new products, such as dimmable glass, are unlikely to be material revenue generators for about 5 years, Deem tells investors.

TODAY'S FREE FLY STORIES

JCP

J.C. Penney

$0.93

0.022 (2.42%)

, DDS

Dillard's

$56.57

0.25 (0.44%)

13:29
05/25/19
05/25
13:29
05/25/19
13:29
Periodicals
Target stock triumphs in brutal week for retail, Barron's says »

Earnings season has been…

JCP

J.C. Penney

$0.93

0.022 (2.42%)

DDS

Dillard's

$56.57

0.25 (0.44%)

KSS

Kohl's

$51.11

-0.04 (-0.08%)

JWN

Nordstrom

$33.50

-0.31 (-0.92%)

M

Macy's

$21.00

-0.27 (-1.27%)

TGT

Target

$81.57

2.17 (2.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jun

JPM

JPMorgan

$109.78

1.14 (1.05%)

, AKZOY

AkzoNobel

$0.00

(0.00%)

13:24
05/25/19
05/25
13:24
05/25/19
13:24
Periodicals
Microsoft, JPMorgan among dividend champions, Barron's says »

Among the companies that…

JPM

JPMorgan

$109.78

1.14 (1.05%)

AKZOY

AkzoNobel

$0.00

(0.00%)

XOM

Exxon Mobil

$74.12

0.33 (0.45%)

MSFT

Microsoft

$126.23

0.04 (0.03%)

CMWAY

Commonwealth Bank of Australia

$0.00

(0.00%)

SIEGY

Siemens

$0.00

(0.00%)

T

AT&T

$32.29

0.15 (0.47%)

RDS.A

Royal Dutch Shell

$63.29

0.84 (1.35%)

RHHBY

Roche

$0.00

(0.00%)

NVS

Novartis

$87.49

3.03 (3.59%)

BHP

BHP Group

$52.47

1.18 (2.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 29

    May

  • 29

    May

  • 31

    May

  • 03

    Jun

  • 03

    Jun

  • 03

    Jun

  • 05

    Jun

  • 08

    Jun

  • 10

    Jun

  • 10

    Jun

  • 11

    Jun

  • 11

    Jun

  • 12

    Jun

  • 20

    Jun

  • 23

    Jun

  • 16

    Jul

  • 24

    Jul

  • 06

    Aug

  • 18

    Aug

  • 19

    Aug

  • 02

    Sep

  • 04

    Nov

GM

General Motors

$35.13

0.01 (0.03%)

, TSLA

Tesla

$190.80

-4.7 (-2.40%)

13:19
05/25/19
05/25
13:19
05/25/19
13:19
Periodicals
Tesla stock in trouble, Barron's says »

Tesla (TSLA) stock is the…

GM

General Motors

$35.13

0.01 (0.03%)

TSLA

Tesla

$190.80

-4.7 (-2.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

  • 05

    Jun

  • 11

    Jun

  • 01

    Aug

RNLSY

Renault

$0.00

(0.00%)

13:14
05/25/19
05/25
13:14
05/25/19
13:14
Periodicals
Renault stock may rally, Barron's says »

Shares of French auto…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FMC

FMC Corporation

$70.88

-0.47 (-0.66%)

, DWDP

DowDuPont

$31.10

0.16 (0.52%)

13:11
05/25/19
05/25
13:11
05/25/19
13:11
Periodicals
DowDuPont spinoff a new agriculture stock, FMC safer bet, Barron's says »

The crop-protection and…

FMC

FMC Corporation

$70.88

-0.47 (-0.66%)

DWDP

DowDuPont

$31.10

0.16 (0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 25

    Jun

MGM

MGM Resorts

$25.55

0.19 (0.75%)

13:03
05/25/19
05/25
13:03
05/25/19
13:03
Periodicals
MGM Resorts looks like an attractive gambling play, Barron's says »

MGM Resorts (MGM) stock…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

PYPL

PayPal

$109.82

-0.09 (-0.08%)

, AXP

American Express

$119.52

1.07 (0.90%)

12:30
05/25/19
05/25
12:30
05/25/19
12:30
Periodicals
Big tech failed to dethrone credit cards, Barron's says »

Rather than being cut out…

PYPL

PayPal

$109.82

-0.09 (-0.08%)

AXP

American Express

$119.52

1.07 (0.90%)

MA

MasterCard

$251.40

1.57 (0.63%)

V

Visa

$162.72

1.2 (0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 03

    Jun

  • 05

    Jun

  • 06

    Jun

  • 11

    Jun

  • 25

    Jun

  • 13

    Nov

GOOG

Alphabet

$1,132.99

-7.56 (-0.66%)

, GOOGL

Alphabet Class A

$1,138.90

-5.98 (-0.52%)

07:20
05/25/19
05/25
07:20
05/25/19
07:20
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

GOOG

Alphabet

$1,132.99

-7.56 (-0.66%)

GOOGL

Alphabet Class A

$1,138.90

-5.98 (-0.52%)

MSFT

Microsoft

$126.23

0.04 (0.03%)

AMBA

Ambarella

$38.28

1.07 (2.88%)

ON

ON Semiconductor

$17.68

-0.235 (-1.31%)

NKE

Nike

$82.12

-0.51 (-0.62%)

ADDYY

Adidas

$0.00

(0.00%)

UAA

Under Armour

$23.54

0.075 (0.32%)

UA

Under Armour

$20.91

0.08 (0.38%)

FL

Foot Locker

$44.39

-8.455 (-16.00%)

VMC

Vulcan Materials

$126.28

1.25 (1.00%)

FLR

Fluor

$29.04

0.18 (0.62%)

ACM

Aecom

$31.56

-0.03 (-0.09%)

X

U.S. Steel

$13.63

-0.08 (-0.58%)

AKS

AK Steel

$2.00

-0.155 (-7.21%)

NUE

Nucor

$51.12

-0.27 (-0.53%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$12.85

0.11 (0.86%)

F

Ford

$9.83

-0.02 (-0.20%)

GM

General Motors

$35.13

0.01 (0.03%)

HMC

Honda

$25.45

0.175 (0.69%)

NSANY

Nissan

$0.00

(0.00%)

TM

Toyota

$118.54

1.16 (0.99%)

VWAGY

Volkswagen

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 03

    Jun

  • 03

    Jun

  • 04

    Jun

  • 04

    Jun

  • 05

    Jun

  • 06

    Jun

  • 08

    Jun

  • 10

    Jun

  • 10

    Jun

  • 11

    Jun

  • 12

    Jun

  • 13

    Jun

  • 19

    Jun

  • 19

    Jun

  • 23

    Jun

  • 09

    Jul

  • 24

    Jul

  • 31

    Jul

  • 01

    Aug

  • 06

    Aug

  • 23

    Oct

  • 27

    Oct

UBER

Uber

$41.40

0.94 (2.32%)

17:49
05/24/19
05/24
17:49
05/24/19
17:49
Hot Stocks
Uber board director Ryan Graves intends to resign »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

APTO

Aptose Biosciences

$2.01

0.03 (1.52%)

17:46
05/24/19
05/24
17:46
05/24/19
17:46
Syndicate
Aptose Biosciences files for $40M at-the-market common stock offering »

Piper Jaffray and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

TRNX

Taronis Technologies

$0.48

0.004 (0.84%)

17:26
05/24/19
05/24
17:26
05/24/19
17:26
Syndicate
Breaking Syndicate news story on Taronis Technologies »

Taronis Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USEG

U.S. Energy

$0.45

0.0373 (9.10%)

17:25
05/24/19
05/24
17:25
05/24/19
17:25
Hot Stocks
U.S. Energy discloses Nasdaq notice regarding delayed 10-Q filing »

U.S. Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$179.03

-0.64 (-0.36%)

17:22
05/24/19
05/24
17:22
05/24/19
17:22
Periodicals
Apple sued over allegedly selling users' iTunes data, Bloomberg says »

Apple is being sued by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

SPCB

SuperCom

$1.17

-0.005 (-0.43%)

17:21
05/24/19
05/24
17:21
05/24/19
17:21
Hot Stocks
SuperCom discloses Nasdaq notice regarding delayed 20-F filing »

SuperCom received a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USEG

U.S. Energy

$0.45

0.0373 (9.10%)

17:20
05/24/19
05/24
17:20
05/24/19
17:20
Hot Stocks
U.S. Energy receives noncompliance notice from Nasdaq »

U.S. Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYOV

Myovant Sciences

$12.39

-0.465 (-3.62%)

17:18
05/24/19
05/24
17:18
05/24/19
17:18
Syndicate
Breaking Syndicate news story on Myovant Sciences »

Myovant Sciences files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYOV

Myovant Sciences

$12.39

-0.465 (-3.62%)

17:17
05/24/19
05/24
17:17
05/24/19
17:17
Syndicate
Breaking Syndicate news story on Myovant Sciences »

Myovant Sciences files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$87.49

3.03 (3.59%)

, QGEN

Qiagen

$38.22

-0.255 (-0.66%)

16:57
05/24/19
05/24
16:57
05/24/19
16:57
Hot Stocks
Qiagen launches diagnostic for PIK3CA biomarkers in breast cancer »

Qiagen (QGEN) announced…

NVS

Novartis

$87.49

3.03 (3.59%)

QGEN

Qiagen

$38.22

-0.255 (-0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 31

    May

  • 20

    Jun

  • 06

    Aug

AVH

Avianca

$3.96

0.91 (29.84%)

16:56
05/24/19
05/24
16:56
05/24/19
16:56
Periodicals
ANAC suspends flights, operations of Avianca Brasil, Reuters reports »

Brazil's ANAC said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$179.03

-0.64 (-0.36%)

16:53
05/24/19
05/24
16:53
05/24/19
16:53
Periodicals
Apple acquires startup Tueo Health, CNBC reports »

Apple has bought Tueo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

SHSP

SharpSpring

$16.37

-0.24 (-1.44%)

16:52
05/24/19
05/24
16:52
05/24/19
16:52
Syndicate
Breaking Syndicate news story on SharpSpring »

SharpSpring files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jun

CREG

China Recycling Energy

$0.48

0.005 (1.05%)

16:41
05/24/19
05/24
16:41
05/24/19
16:41
Syndicate
Breaking Syndicate news story on China Recycling Energy »

China Recycling Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FENC

Fennec

$3.88

(0.00%)

16:36
05/24/19
05/24
16:36
05/24/19
16:36
Conference/Events
Fennec management to meet with Wedbush »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 18

    Jun

TD

Toronto-Dominion

$56.66

0.65 (1.16%)

16:35
05/24/19
05/24
16:35
05/24/19
16:35
Syndicate
Breaking Syndicate news story on Toronto-Dominion »

Toronto-Dominion files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
05/24/19
05/24
16:30
05/24/19
16:30
Options
Preliminary option volume of 15.7M today »

Preliminary option volume…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.